[en] In order to evaluate the potential inhibition of the acute anti-osteoclastic activity of salmon calcitonin (SCT) by specific antibodies (Ab), we compared the SCT-induced hypocalcemic effect in young male rabbits with significant titers of high affinity Ab and in matched animals without Ab. Immunization of rabbits was performed by repetitive s.c. injections of SCT and Freund adjuvant. Ab were present in four-fifths of SCT-treated rabbits (Ab+). Their titer varied from 0.8 x 10(-9) to 30 x 10(-9) M/liter and their constant of affinity from 0.97 x 10(9) to 4.2 x 10(9) L/M. Intravenous injection of 1 IU/kg SCT to Ab+ rabbits induced a significant decrease (P less than 0.01) of ionized serum calcium (Ca2+) after 30 minutes (mean +/- SD: -9 +/- 0.6%) and until the 240th minute of the test (-16.7 +/- 4.7%), with a maximum after 120 minutes (-22.6 +/- 2%). This was not significantly different from the hypocalcemic effect measured after the same procedure performed in matched animals without Ab (Ab-): significant decrease in Ca2+ (P less than 0.01) after 30 minutes (-8.2 +/- 2.2%), maximal after 150 minutes (-23.2 +/- 4.9%), and lasting until 210 minutes (-14.5 +/- 3.7%). We conclude that, in the particular model of the male young rabbit, specific anti-SCT Ab do not block or reduce the acute anti-osteoclastic activity of SCT.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Azria, M.
Lismonde, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > Quartier accouchement NDB
Bleicher, M.
Franchimont, N.
Behhar, M.
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Franchimont, P.
Language :
English
Title :
Endogenous Production of Specific Antibodies Does Not Decrease Hypocalcemic Response to Calcitonin in Young Rabbits
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Copp D.H., Davidson A.G.P. (1961) Direct humoral control of parathyroid function in the dog. Proc Soc Exp Biol Med 107:342-344.
Copp D.H., Cameron E.C., Cheney B.A., Davidson A.G.F., Henze K.G. (1962) Evidence for calcitonin. A new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638-649.
Bijvoet O.L.M., Van der Sluys Veer J., Jansen A.P. (1968) Effects of calcitonin on patients with Paget's disease, thyrotoxicosis and hypercalcaemia. Lancet 1:876-881.
Singer F.R. (1977) Human calcitonin treatment of Paget's disease of bone. Clin Orthop Rel Res 127:86-93.
Shai F., Baker R., Wallach S. (1971) The clinical and metabolic effects of porcine calcitonin in Paget's disease of bone. J Clin Invest 50:1927-1940.
Haddad J.G., Birge S.J., Avioli L.V. (1970) Effects of prolonged thyrocalcitonin administration on Paget's disease of bone. N Engl J Med 283:549-555.
Gruber H.E., Ivey J.L., Baylink D.J., Matthews M., Nelp W.B., Sisom K., Chestnut C.H. (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295-303.
Gennari C., Chierichetti S.M., Bigazzi S., Fusi L., Gonelli S., Ferrara R., Zacchei F. (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455-464.
Mazzuoli G.F., Passeri M., Gennari C., Minisola S., Antonelli R., Valtorta C., Palummeri E., Cervellin G.F., Gonnelli S., Francini G. (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study. Calcif Tissue Int 38:3-8.
Overgaard K., Riis B.J., Christiansen C., Hansen M.A. (1989) Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 299:477-479.
Overgaard K., Riis B.J., Christiansen C., Podenphant J., Johansen J. (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442.
Reginster J.Y., Denis D., Albert A., Deroisy R., Lecart M.P., Fontaine M.A., Lambelin P., Franchimont P. (1987) One-year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483.
Hosking D.J., Denton L.B., Cadge B., Martin T.J. (1979) Functional significance of antibody formation after long-term salmon calcitonin therapy. Clin Endocrinol 10:243-252.
Singer F.R., Aldred J.C., Neer R.M., Krane S.M., Potts J.T., Block K.J. (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331-2332.
Singer F.R., Fredericks R.S., Minkin C. (1980) Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired resistance. Arthritis Rheum 23:1148-1153.
Reginster J.Y., Gennari C., Mautalen C., Deroisy C., Denis D., Lecart M.P., Vandalem J.L., Collette J., Franchimont P. (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 19:83-86.
Grauer A., Raue F., Schneider H.G., Frank-Raue K., Ziegler R. (1990) In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. J Bone Miner Res 5:387-391.
Muff R., Dambacher M.A., Fischer A. (1991) Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int 1:72-75.
Greenwood F.C., Hunter W.M., Glover J.S. (1963) Preparation of iodine-131 labelled human growth hormone of high specific radioactivity. Biochem J 89:114-123.
Franchimont P., Heynen G. Parathormone and calcitonin radioimmunoassay in various medical and osteoarticular disorders, Masson Eds, New York, Paris, Barcelona, Milan; 1976.
Scatchard G. (1949) The attraction of proteins for small molecules and ions. Annals of the New York Academy of Sciences 51:660-672.
Guttmann S. (1981) Chemistry and structure-activity relationship of natural and synthetic calcitonins. Calcitonin 1980, chemistry, physiology, pharmacology and clinical aspects , A., Pecile, Excerpta Medica Publishers, Amsterdam, Oxford, Princeton; 11-24.
Reginster J.Y., Azria M., Gaspar S., Attinger M., Albert A., Bleicher M., Almer S., Deroisy R., Behhar C., Franchimont P. (1990) The effect of salmon calcitonin on blood ionized calcium in the presence of anti-salmon-calcitonin antibodies (from pagetic patients) in young rabbits. Curr Ther Res 47:1063-1072.
Zerbe G.O. (1979) Randomization analysis of the completely randomized design extended to growth and response curves. Journal of the American Statistical Association 74:215-221.
Galante L., Joplin G.F., Mac Intyre I., Woodhouse N.J. (1973) The calcium lowering effect of synthetic human, porcine and salmon calcitonin in patients with Paget's disease of bone. Clin Sci 44:605-610.
Azria M., Attinger M., Schupfer H., Tanner P. (1984) Comparison of the hypocalcaemic activities of three calcitonins using a new biological method. Calcitonin 1984 , W., Doepfner, Excerpta Medica Publishers, Amsterdam, Oxford, Princeton; 104-110.
Levy F., Muff R., Dotti-Sigrist S., Dambacher M.A., Fischer J.A. (1988) Formation of neutralizing antibodies during intranasal synthetic calcitonin treatment of Paget's disease of bone. The Journal of Clinical Endocrinology & Metabolism 67:541-545.
Rojannasathit S., Rosenberg E., Haddad J.G. (1974) Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin. Lancet 2:1412-1425.
Singer F.R., Villanueva R., Ginger K. (1989) Acquired resistance to salmon and human calcitonin during treatment of Paget's disease of bone. Calcif Tissue Int S 87:N32.
Muff R., Dambacher M.A., Perrenoud A., Simon C., Fischer J.A. (1990) Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin. Am J Med 89:181-184.
Reginster J.Y., Almer S., Gaspar S., Albert A., Deroisy R., Franchimont P. (1989) Evidence that specific antibodies do not reduce salmon calcitonin activity in vivo. Antibody, immunoconjugates and radiopharmaceuticals 2:117-124.
Berson S.A., Yallow R.S., Bauman A., Rotschild M.A., Newerly K. (1956) Insulin I-131 metabolism in human subjects: demonstration of insulin-binding globulin in the circulation of insulin-treated subjects. J Clin Invest 35:170-190.
Roth J., Glick M., Klein L.A., Peterson M.J. (1966) Specific antibodies to vasopressin in man. J Clin Invest 26:671-675.
Melick R.A., Gill J.R., Berson S.A., Yallow R.S., Batter F.C., Potts J.T., Aurbach G.D. (1967) Antibody and clinical resistance to parathormone. N Engl J Med 276:144-147.
Berson S.A., Yallow R.S. (1959) Quantitative aspects of the reaction between insulin-binding antibody. J Clin Invest 38:1996-2016.
Greenberg P.B., Doyle F.M., Fisher H.T., Hillyard C.J., Joplin J.F., Penncock J., MacIntyre I. (1974) Treatment of Paget's disease of bone with synthetic human calcitonin. Am J Med 56:867-870.
Bouizar Z., Rostene W.H., Milhaud G. (1987) Down regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci USA 84:5125-5128.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
